Loading
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Previous close
$12.77
−$0.33 · -2.52%
After-hours
$12.77
$0.00 · 0.00%
Oct 7, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Day range
Current $12.77
52-week range
Current $12.77
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
85
Deep Value
Sentiment
70
Bullish
Risk
42
Elevated Risk
Momentum
69
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Day range
Current $12.77
52-week range
Current $12.77
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 568.09M USD | 573.28M USD | 512.35M USD | 512.12M USD | 430.9M USD |
| Cost of goods sold | 185.66M USD | 185.05M USD | 184.15M USD | 181.04M USD | 128.19M USD |
| Gross profit | 382.43M USD | 388.23M USD | 328.19M USD | 331.08M USD | 302.71M USD |
| Research and development | 12.11M USD | 13.64M USD | 13.45M USD | 23.85M USD | 19.04M USD |
| Selling, general, and administrative | 311.77M USD | 327.09M USD | 303.88M USD | 332.13M USD | 254.25M USD |
| Operating expenses | 323.88M USD | 400.21M USD | 409.92M USD | 498.31M USD | 290.65M USD |
| Interest expense | 26.49M USD | 38.79M USD | 40.68M USD | 12.02M USD | 1.11M USD |
| Depreciation and amortization | 47.01M USD | 49.56M USD | 57.37M USD | 55.4M USD | 34.88M USD |
| Operating income | 58.55M USD | −11.98M USD | −81.73M USD | −167.23M USD | 12.06M USD |
| Net income | 22.73M USD | −33.54M USD | −156.23M USD | −158.7M USD | 19.38M USD |
Company facts updated Oct 8, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$18.33
43.54% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Avantis U.S. Small Cap Value ETFAVUV23.15M0.07%30.86B USD0.25%$119.13-1.11%
iShares Russell 2000 ETFIWM16.5M0.02%78.56B USD0.19%$277.7-1.29%
Vanguard Morningstar Total Stock Market ETFVTI15.88M0.00%2.3T USD0.03%$381.03-0.40%
Vanguard Extended Market ETFVXF7.43M0.01%95.4B USD0.05%$233.49-1.56%
iShares Russell 2000 Growth ETFIWO5.85M0.04%14.25B USD0.24%$355.37-1.43%
Dimensional - US Small Cap ETFDFAS5.84M0.02%34.14B USD0.31%$77.92-1.38%
Fidelity Enhanced Small Cap ETFFESM4.17M0.06%6.41B USD0.28%$45.22-1.14%
Vanguard Russell 2000 ETFVTWO3.78M0.02%18B USD0.06%$112.21-1.26%Avantis U.S. Small Cap Value ETFAVUViShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWODimensional - US Small Cap ETFDFASFidelity Enhanced Small Cap ETFFESMVanguard Russell 2000 ETFVTWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
